Xoma Corp. Company Profile (NASDAQ:XOMA)

About Xoma Corp.

Xoma Corp. logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: XOMA
  • CUSIP: 98419J10
Key Metrics:
  • Previous Close: $5.49
  • 50 Day Moving Average: $0.96
  • 200 Day Moving Average: $0.73
  • 52-Week Range: $0.34 - $7.33
  • Trailing P/E Ratio: 499.09
  • Foreward P/E Ratio: -0.57
  • P/E Growth: -0.05
  • Market Cap: $662.00M
  • Outstanding Shares: 120,583,000
  • Beta: 2.87
  • Net Margins: 2.46%
  • Return on Assets: -34.29%
  • Debt-to-Equity Ratio: -1.68%
  • Current Ratio: 1.50%
  • Quick Ratio: 1.50%
Additional Links:
Companies Related to Xoma Corp.:

Analyst Ratings

Consensus Ratings for Xoma Corp. (NASDAQ:XOMA) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $5.58 (1.55% upside)

Analysts' Ratings History for Xoma Corp. (NASDAQ:XOMA)
DateFirmActionRatingPrice TargetDetails
10/19/2016WedbushReiterated RatingOutperform$17.00View Rating Details
9/19/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
8/5/2016Jefferies GroupReiterated RatingHoldView Rating Details
3/12/2016Piper Jaffray Cos.Reiterated RatingHoldView Rating Details
3/11/2016Royal Bank Of CanadaReiterated RatingSector Perform$2.00View Rating Details
9/15/2015Deutsche Bank AGReiterated RatingSellView Rating Details
7/22/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
6/29/2015SusquehannaDowngradePositive -> NeutralView Rating Details
5/5/2015Credit Suisse Group AGReiterated RatingNeutral$5.00View Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Xoma Corp. (NASDAQ:XOMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)ViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Xoma Corp. (NASDAQ:XOMA)
Current Year EPS Consensus Estimate: $-9.36 EPS
Next Year EPS Consensus Estimate: $-9.6 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20162($0.15)($0.09)($0.12)
Q3 20162($0.14)($0.10)($0.12)
Q4 20162($0.14)($0.12)($0.13)
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.13)($0.13)($0.13)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)


Dividend History for Xoma Corp. (NASDAQ:XOMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xoma Corp. (NASDAQ:XOMA)
Insider Ownership Percentage: 3.92%
Institutional Ownership Percentage: 17.13%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.16View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.00View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.80View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.08View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.19View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.80View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.00View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.00View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.00View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.00View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.00View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.84View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.32View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.00View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.00View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.28View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.72View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.20View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Xoma Corp. (NASDAQ:XOMA)
investopedia.com logoXoma's Pediatric Insulin Study Gets UK OK (XOMA) | Investopedia - Investopedia (NASDAQ:XOMA)
www.investopedia.com - October 20 at 8:29 PM
investopedia.com logoXoma Phase 2 Pediatric Trial Wins UK Nod (XOMA) (NASDAQ:XOMA)
www.investopedia.com - October 20 at 8:29 PM
News IconXOMA Corp (NASDAQ:XOMA) Heffx Trading Outlook - Live Trading News (NASDAQ:XOMA)
www.livetradingnews.com - October 20 at 7:34 AM
smarteranalyst.com logoStock Update (NASDAQ:XOMA): XOMA Corp Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical ... - Smarter Analyst (NASDAQ:XOMA)
www.smarteranalyst.com - October 20 at 7:34 AM
marketexclusive.com logoXOMA Corp (NASDAQ:XOMA) Files An 8-K - Market Exclusive - Market Exclusive (NASDAQ:XOMA)
marketexclusive.com - October 20 at 7:34 AM
streetinsider.com logoXOMA's (XOMA) Proposed XOMA 358 Phase 2 in CHI Accepted by U.K. MHRA (NASDAQ:XOMA)
www.streetinsider.com - October 19 at 7:49 PM
reuters.com logoBRIEF-XOMA says regulatory body in Germany approves plan to conduct repeat-dose clinical study in congenital hyperinsulinism patients over age of 12 (NASDAQ:XOMA)
www.reuters.com - October 19 at 7:49 PM
marketexclusive.com logoXOMA Corp (NASDAQ:XOMA) Files An 8-K (NASDAQ:XOMA)
marketexclusive.com - October 19 at 7:49 PM
publicnow.com logoXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism (NASDAQ:XOMA)
www.publicnow.com - October 19 at 7:49 PM
feeds.benzinga.com logo15 Biggest Mid-Day Losers For Wednesday (NASDAQ:XOMA)
feeds.benzinga.com - October 19 at 1:41 PM
investopedia.com logoXoma Declares 1-for-20 Reverse Stock Split (XOMA) (NASDAQ:XOMA)
www.investopedia.com - October 18 at 7:59 PM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters (NASDAQ:XOMA)
biz.yahoo.com - October 18 at 7:59 PM
biz.yahoo.com logoSplits Calendar: XOMA splits before market open today (1:20 ratio) (NASDAQ:XOMA)
biz.yahoo.com - October 18 at 7:59 PM
capitalcube.com logoETF’s with exposure to XOMA Corp. : October 18, 2016 (NASDAQ:XOMA)
www.capitalcube.com - October 18 at 7:59 PM
investopedia.com logoXoma Declares 1-for-20 Reverse Stock Split (XOMA) - Investopedia (NASDAQ:XOMA)
www.investopedia.com - October 17 at 8:03 PM
News IconTraders Watch List: XOMA Corp (NASDAQ:XOMA), Aerohive Networks Inc (NYSE:HIVE), Square Inc (NYSE:SQ) - NYSE Journal (press release) (NASDAQ:XOMA)
stockznews.com - October 17 at 8:03 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention XOMA Corp (NASDAQ:XOMA), Peregrine Pharmaceuticals (NASDAQ ... - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - October 17 at 8:03 PM
investopedia.com logoXoma Sets 1-for-20 Reverse Stock Split (XOMA) (NASDAQ:XOMA)
www.investopedia.com - October 17 at 8:03 PM
nasdaq.com logoBe All Ears For ABEO, Lucentis PFS Gets FDA Nod, XOMA Effects Stock Split (NASDAQ:XOMA)
www.nasdaq.com - October 17 at 5:37 AM
4-traders.com logoXOMA : Announces Reverse Stock Split (NASDAQ:XOMA)
www.4-traders.com - October 15 at 7:52 PM
streetinsider.com logoXOMA (XOMA) Plans 1-for-20 Reverse Stock Split (NASDAQ:XOMA)
www.streetinsider.com - October 14 at 7:58 PM
reuters.com logoBRIEF-Xoma announces reverse stock split (NASDAQ:XOMA)
www.reuters.com - October 14 at 7:58 PM
publicnow.com logoXOMA Announces Reverse Stock Split (NASDAQ:XOMA)
www.publicnow.com - October 14 at 7:58 PM
News IconHistory of XOMA Corporation (NASDAQ:XOMA) stock price after earnings - The Independent Republic (NASDAQ:XOMA)
theindependentrepublic.com - October 13 at 8:26 PM
News IconXOMA Corporation – Product Pipeline Review Market Research Report – 2016: Radiant Insights (NASDAQ:XOMA)
www.digitaljournal.com - October 12 at 11:44 AM
News IconBiotech news that matter for investors: Opko Health, Inc. (NASDAQ:OPK), XOMA Corporation (NASDAQ:XOMA) - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - October 11 at 5:28 AM
News IconBiotech stocks for your portfolio: XOMA Corporation (XOMA), Kite ... - The Independent Republic (NASDAQ:XOMA)
theindependentrepublic.com - October 10 at 7:39 PM
News IconSmall Cap in Focus: A Closer Look at XOMA Corporation (NASDAQ:XOMA) - Duncan Research (NASDAQ:XOMA)
www.duncanindependent.com - October 10 at 7:39 PM
News IconEPS Traction in Focus for XOMA Corporation (NASDAQ:XOMA) - CSZ News (NASDAQ:XOMA)
cincysportszone.com - October 8 at 5:31 AM
News IconTrading the Biotech News: XOMA Corporation (NASDAQ:XOMA), CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - October 7 at 5:39 AM
News IconStock Update on Earnings & Estimates for XOMA Corporation (NASDAQ:XOMA) - CSZ News (NASDAQ:XOMA)
cincysportszone.com - October 5 at 7:59 PM
News IconThe Statistics Don't Lie: XOMA Corporation (NASDAQ:XOMA) Earnings Preview - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - October 4 at 7:40 PM
capitalcube.com logoETF’s with exposure to XOMA Corp. : September 30, 2016 (NASDAQ:XOMA)
www.capitalcube.com - September 30 at 7:24 PM
stocksdaily.net logoAnalysts Set EPS Target of $-0.12 For XOMA Corporation (NASDAQ ... - Stocks Daily (NASDAQ:XOMA)
www.stocksdaily.net - September 27 at 8:05 PM
News IconHow Analysts Feel About XOMA Corp (NASDAQ:XOMA)? | Kentucky ... - Post News (NASDAQ:XOMA)
www.kentuckypostnews.com - September 27 at 8:17 AM
News IconKeen Investors Find News on XOMA Corporation (NASDAQ:XOMA) - Duncan Research (NASDAQ:XOMA)
www.duncanindependent.com - September 23 at 7:33 PM
News IconIntraday Active Biotech Stocks News: Cara Therapeutics Inc ... - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - September 22 at 5:29 AM
News IconXOMA Corp (NASDAQ:XOMA) Says XOMA 358 Trial Meets Expectations - Scibility Media (NASDAQ:XOMA)
scibilitymedia.com - September 21 at 12:01 PM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans (NASDAQ:XOMA)
biz.yahoo.com - September 20 at 8:03 AM
News IconHC Stocks Reports! XOMA Corp (XOMA), ImmunoGen, Inc ... - share market updates (press release) (NASDAQ:XOMA)
sharemarketupdates.com - September 19 at 3:16 PM
smarteranalyst.com logoWedbush Reduces Price Target On XOMA Corp (XOMA), But Remains Positive - Smarter Analyst (NASDAQ:XOMA)
www.smarteranalyst.com - September 19 at 3:16 PM
investors.com logoOracle shares fall despite reiterated recommendation (NASDAQ:XOMA)
www.proactiveinvestors.com - September 18 at 5:40 AM
streetinsider.com logoXOMA (XOMA) Updates on XOMA 358 Phase 2; PBS Study Showed Some Effect on Glucose, Insulin (NASDAQ:XOMA)
www.streetinsider.com - September 18 at 5:40 AM
4-traders.com logoXOMA : Reports Second Quarter 2016 Achievements and Financial Results (NASDAQ:XOMA)
www.4-traders.com - September 18 at 5:40 AM
smarteranalyst.com logoAnalysts Weigh In on Two Falling Biotech Stocks: Novavax, Inc. (NVAX) and XOMA Corp (XOMA) - Smarter Analyst (NASDAQ:XOMA)
www.smarteranalyst.com - September 16 at 7:51 PM
investopedia.com logoXOMA Reports Success in Insulin Trials (XOMA) (NASDAQ:XOMA)
www.investopedia.com - September 16 at 7:51 PM
News IconAnalysts Valuations For Two Stocks: XOMA Corp (NASDAQ:XOMA), Tiffany & Co. (NYSE:TIF) - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - September 16 at 11:50 AM
smarteranalyst.com logoStock Update (NASDAQ:XOMA): XOMA Corp Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies - Smarter Analyst (NASDAQ:XOMA)
www.smarteranalyst.com - September 16 at 11:50 AM
finance.yahoo.com logo2:55 am XOMA provides update from ongoing Phase 2 XOMA 358 clinical studies; plans to advance XOMA 358 to multi-dose Phase 2b studies (NASDAQ:XOMA)
finance.yahoo.com - September 16 at 11:50 AM
publicnow.com logoXOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies (NASDAQ:XOMA)
www.publicnow.com - September 15 at 8:20 PM


Xoma Corp. (NASDAQ:XOMA) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by MarketBeat.com Staff